Clinical practice guidelines recommend that cerebral venous thrombosis (CVT) be managed with long-term anticoagulant therapy using warfarin or low-molecular-weight heparin (LMWH) for 3 to 12 months. However, oral factor Xa inhibitors may offer preferable alternative treatment options for these patients.
Objective:
The primary objective was to determine the effectiveness and safety of rivaroxaban or apixaban compared with warfarin or enoxaparin as long-term anticoagulation therapy for patients with a new diagnosis of CVT.
Methods:
This was a single-center retrospective review of patients with newly diagnosed CVT who received acute and maintenance anticoagulation treatment. Study groups compared patients who received warfarin, enoxaparin, or an oral factor Xa inhibitor as their maintenance anticoagulant. The primary outcome was recurrent thrombotic events while on anticoagulation. Secondary outcomes included modified Rankin Scale, improved cerebral venous sinus opacification, duration of anticoagulant therapy, bleeding events during anticoagulant therapy, and adverse effects.
Results:
A total of 119 patients were included in the analysis: warfarin (89), enoxaparin (11), and oral factor Xa inhibitor (19). The risk of recurrent thrombotic events were 11.2%, 0%, and 10.5% in the warfarin, enoxaparin, and oral factor Xa inhibitor treatment groups, respectively (P = 0.7635). There were no significant between-group differences observed regarding any of the secondary outcomes.
Conclusions:
Although the sample size is limited, these findings indicate that oral factor Xa inhibitors are a reasonable treatment option for patients with CVT. There was a trend toward more persistent symptoms in patients on warfarin, suggesting a potential improvement in recovery among patients that received an oral factor Xa inhibitor.
RaoSKIbrahimMHanniCM, et al. Apixaban for the treatment of cerebral venous thrombosis: a case series. J Neurol Sci. 2017;381:318-320.
2.
SaposnikGBarinagarrementeriaFBrownRDJr, et al. Diagnosis and management of cerebral venous thrombosis: a statement for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2011; 42:1158-1192.
3.
FerroJMCanhãoPStamJBousserMGBarinagarrementeriaF; ISCVT Investigators. Prognosis of cerebral vein and dural sinus thrombosis: results of the International Study on Cerebral Vein and Dural Sinus Thrombosis (ISCVT). Stroke. 2004;35:664-670.
4.
FurieKLKasnerSEAdamsRJ, et al. Guidelines for prevention of stroke in patients with ischemic stroke or transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2011;42:227-276.
5.
FerroJMBousserMGCanhãoP, et al. European Stroke Organization guideline for the diagnosis and treatment of cerebral venous thrombosis—endorsed by the European Academy of Neurology. Eur Stroke J. 2017;2:195-221.
6.
FerroJMCoutinhoJMDentaliF, et al. Safety and efficacy of dabigatran etexilate vs dose-adjusted warfarin in patients with cerebral venous thrombosis. JAMA Neurol. 2019;76:1457-1465.
GrangerCBAlexanderJHMcMurrayJJ, et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2011;365:981-992.
9.
WeyckerDLiXWygantGD, et al. Effectiveness and safety of apixaban versus warfarin as outpatient treatment of venous thromboembolism in US clinical practice. Thromb Haemost. 2018;118:1951-1961.
10.
StantonBEBaraschNSTellorKB.Comparison of the safety and effectiveness of apixaban versus warfarin in patients with severe renal impairment. Pharmacotherapy. 2017;37:412-419.
11.
PatelMRMahaffeyKWGargJ, et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med. 2011;365:883-891.
12.
AgnelliGBullerHRCohenA, et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med. 2013;369:799-808.
13.
BüllerHRPrinsMHLensinAW, et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med. 2012;366:1287-1297.
14.
BauersachsRBerkowitzSDBrennerB, et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med. 2010;363:2499-2510.
15.
PrinsMHLensingAWBauersachsR, et al. Oral rivaroxaban versus standard therapy for the treatment of symptomatic venous thromboembolism: a pooled analysis of the EINSTEIN-DVT and PE randomized studies. Thromb J. 2013;11:21.
16.
SchulmanSKearonCKakkarAK, et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med. 2009;361:2342-2352.
17.
SchulmanSKakkarAKGoldhaberSZ, et al. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation. 2014;129:764-772.
18.
Hokusai-VTE Investigators; BüllerHRDécoususH, et al. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med. 2013;369:1406-1415.
19.
GiuglianoRPRuffCTBraunwaldE, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369:2093-2104.
20.
Gómez-OutesATerleira-FernándezAILecumberriRSuárez-GeaMVargas-CastrillónE.Direct oral anticoagulants in the treatment of acute venous thromboembolism: a systematic review and meta-analysis. Thromb Res. 2014;134:774-782.
21.
van EsNCoppensMSchulmanSMiddeldorpSBüllerHR.Direct oral anticoagulants compared with vitamin K antagonists for acute venous thromboembolism: evidence from phase 3 trials. Blood. 2014;124:1968-1975.
22.
AfzalSKHasanSSBabarZU.A systematic review of patient-reported outcomes associated with the use of direct-acting oral anticoagulants. Br J Clin Pharmacol. 2019;85:2652-2667.
23.
RaskobGEvan EsNVerhammeP, et al. Edoxaban for the treatment of cancer-associated venous thromboembolism. N Engl J Med. 2018;378:615-624.
24.
WittkowskyAK.Barriers to the long-term use of low-molecular weight heparins for treatment of cancer-associated thrombosis. J Thromb Haemost. 2006;4:2090-2091.
25.
AyCBeyer-WestendorfJPabingerI.Treatment of cancer-associated venous thromboembolism in the age of direct oral anticoagulants. Ann Oncol. 2019;30:897-907.
26.
SchulmanSKearonC; Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost. 2005;3:692-694.
27.
HarrisPATaylorRThielkeRPayneJGonzalezNCondeJG.Research Electronic Data Capture (REDCap)—a metadata-driven methodology and workflow process for providing translational research informatics support. J Biomed Inform. 2009;42:377-381.
28.
R Core Team. R: A Language and Environment for Statistical Computing. R Foundation for Statistical Computing; 2016. Accessed August 10, 2020. https://www.R-project.org/
29.
KearonCAklEAOrnelasJ, et al. Antithrombotic therapy for VTE disease: CHEST Guideline and Expert Panel Report. Chest. 2016;149:315-352.
30.
Gosk-BierskaIWysokinskiWBrownRDJr, et al. Cerebral venous sinus thrombosis: incidence of venous thrombosis recurrence and survival. Neurology. 2006;67:814-819.
31.
FerroJMLopesMGRosasMJFerroMAFontesJ; Cerebral Venous Thrombosis Portuguese Collaborative Study Group. Long-term prognosis of cerebral vein and dural sinus thrombosis: results of the VENOPORT study. Cerebrovasc Dis. 2002;13:272-278.
32.
PreterMTzourioCAmeriABousserMG.Long-term prognosis in cerebral venous thrombosis: follow-up of 77 patients. Stroke. 1996;27:243-246.
33.
MaquedaVMThijsV.Risk of thromboembolism after cerebral venous thrombosis. Eur J Neurol. 2006;13:302-305.
34.
MartinelliIBucciarelliPPassamontiSMBattaglioliTPrevitaliEMannucciPM.Long-term evaluation of the risk of recurrence after cerebral sinus-venous thrombosis. Circulation. 2010;121:2740-2746.
35.
RusinGWypasekEPapuga-SzelaEZukJUndasA.Direct oral anticoagulants in the treatment of cerebral venous sinus thrombosis: a single institution’s experience. Neurol Neurochir Pol. 2019;53:384-387.
36.
CovutFKewanTPerezOFloresMHaddadADawH.Apixaban and rivaroxaban in patients with cerebral venous thrombosis. Thromb Res. 2019;173:77-78.
37.
TalamoLDouvasMMacikBGOrnanD.Successful treatment with apixaban of sinus venous thrombosis due to pegylated asparaginase in a young adult with T cell acute lymphoblastic leukemia: case report and review of management. Ann Hematol. 2017;96:691-693.
38.
GeisbüschCRichterDHerwehCRinglebPANagelS.Novel factor Xa inhibitor for the treatment of cerebral venous and sinus thrombosis: first experience in 7 patients. Stroke. 2014;45:2469-2471.
39.
MutgiSAGroseNABehrouzR.Rivaroxaban for the treatment of cerebral venous thrombosis. Int J Stroke. 2015;10(suppl A100):167-168.
40.
AnticoliSPezzellaFRScifoniGFerrariCPozzessereC.Treatment of cerebral venous thrombosis with rivaroxaban. J Biomed Sci. 2016;5:3.
